mAb Development

Jan 04, 2016
BioPharm International
BioPharm highlights the monoclonal antibodies that may gain United States regulatory approval in 2016.
Dec 10, 2015
The company will in-license a novel antibody, which has a conformation that is associated with increased therapeutic efficacy.
Oct 29, 2015
By BioPharm International Editors
The novel antibody-engineering platform works differently than most of the currently employed antibody-modifying technologies, according to UM Baltimore.
Sep 28, 2015
By BioPharm International Editors
Although the Committee for Medicinal Products for Human Use (CHMP) gave Blincyto a positive opinion, full approval of the drug in the EMA will rely on additional clinical studies.
Sep 18, 2015
The fully humanized monoclonal antibody is licensed to Bristol-Myers Squibb.
Sep 16, 2015
Under terms of the agreement, Amgen will license Xencor’s XmAb technology platform for five Amgen programs and one Xencor program.
Aug 14, 2015
BioPharm International
By BioPharm International Editors
Licenses could potentially bring antibody R&D to areas beyond oncology, such as diabetes treatments.
Jul 31, 2015
By BioPharm International Editors
CMC Biologics and River Vision Development announce manufacturing agreement for RV001, a monoclonal antibody to treat Grave’s orbitopathy.
Jul 29, 2015
A broad indication for GSK’s investigational mAb mepolizumab, coupled with an upcoming FDA decision date, could give the manufacturer a competitive advantage in the biologic asthma market.
Jul 21, 2015
By BioPharm International Editors
The $19.7 million contract will assist Emergent with the development of cGMP lots of three Ebola mAbs.
lorem ipsum